China’s CAR T-Cell Therapy Industry Booms With Shanghai At Center

 
• By Mainbayar Badarch
  
Generate a summary of this article
Listen to this article
Beta

According to China Pharmaceutical Innovation and Research Development Association, in the first quarter of 2024 a total of 44 cell therapies in the domestic cell therapy field made clinical application progress, including 28 immune cell therapies and 16 stem cell therapies.  

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration

As of March 2024, five CART-cell therapies had been approved for marketing in China, including Yescarta introduced by Fosun Kite from Gilead Sciences, Inc., Ruiqioren by Innovent Biologics, Inc., Ikioren by Innovent Biologics/Reindeer Healthcare, Nakioren by Heyuan Biology and Zewokioren by Coherus Pharmaceuticals. Other major Chinese domestic firms making progress are Gracell Biotechnology (Shanghai) Co., Ltd., and Nanjing Legend Biotechnology Co., Ltd.

The average selling price of therapies is around CNY1.16 million per dose ($160,220/dose), which is CNY840,000 yuan/dose lower than the...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Global Vision

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

This is a test

 
• By Eleanor Malone

Just running through to check Confluence instructions make sense

H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By Ashley Yeo

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 
• By Anabel Costa-Ferreira

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting